{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001739174","name":"BiomX Inc.","summary":"BiomX Inc. is a clinical-stage company developing phage-based therapies to target and kill specific harmful bacteria associated with chronic diseases. Its lead programs include BX011 (fixed phage cocktail for diabetic foot infections) and BX211 (personalized phage therapy for diabetic foot osteomyelitis), both targeting Staphylococcus aureus. The company discontinued BX004 (cystic fibrosis) and BX005 (atopic dermatitis) programs. In December 2025, its Israeli subsidiary commenced insolvency proceedings, and the company is pursuing strategic alternatives.","people":[],"products":[{"name":"BX011","type":"platform","description":"Fixed multi-phage cocktail for treatment of diabetic foot infections associated with Staphylococcus aureus; Phase 2a clinical trial planned."},{"name":"BX211","type":"platform","description":"Personalized phage therapy for diabetic foot osteomyelitis associated with S. aureus; positive Phase 2 trial results announced March 2025."},{"name":"BX004","type":"platform","description":"Phage cocktail for chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients; discontinued December 2025."},{"name":"BX005","type":"platform","description":"Topical phage product targeting S. aureus for atopic dermatitis; discontinued in 2024."}],"partnerships":[{"partner_name":"U.S. Defense Health Agency","partnership_type":"development","description":"Ongoing discussions to advance BX011 Phase 2a clinical trial for diabetic foot infections.","start_date":null},{"partner_name":"National Institutes of Health (NIH)","partnership_type":"development","description":"Supporting NIH and Antibacterial Resistance Leadership Group Phase 1b/2 study of phage therapy targeting P. aeruginosa in cystic fibrosis patients.","start_date":null}],"affiliations":[],"origin":{"leaf":"a80acc419bd20f564d93018d430ad5c753ac4375dbfb932ce968098c06e15818","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"46e8be90f7511236cd01ba12ee4449d83e17556ead3245dd63d91f947dcad612","parent":"49bed78952ca8593ea1dbe8143bee5402d927f1c0d69483d1c8878b9657d5d58","source":"0001213900-26-018231","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":74,"hourly_limit":500,"remaining":426,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}